GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regado Biosciences Inc (NAS:RGDO) » Definitions » Price-to-Owner-Earnings

Regado Biosciences (Regado Biosciences) Price-to-Owner-Earnings : (As of May. 16, 2024)


View and export this data going back to . Start your Free Trial

What is Regado Biosciences Price-to-Owner-Earnings?

As of today (2024-05-16), Regado Biosciences's share price is $0.00. Regado Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Regado Biosciences's Price-to-Owner-Earnings or its related term are showing as below:


RGDO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.09
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-16), Regado Biosciences's share price is $0.00. Regado Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $0.00. Therefore, Regado Biosciences's PE Ratio for today is N/A.

As of today (2024-05-16), Regado Biosciences's share price is $0.00. Regado Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, Regado Biosciences's PE Ratio without NRI for today is N/A.


Regado Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Regado Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regado Biosciences Price-to-Owner-Earnings Chart

Regado Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Price-to-Owner-Earnings
- - - - -

Regado Biosciences Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regado Biosciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Regado Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regado Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regado Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Regado Biosciences's Price-to-Owner-Earnings falls into.



Regado Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Regado Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regado Biosciences  (NAS:RGDO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Regado Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Regado Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Regado Biosciences (Regado Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
Executives
Domain Parters Vii L P 10 percent owner ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Associates Domain 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p. 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Kim P. Kamdar 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Patrick J Heron director 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Dp Vii Associates Lp 10 percent owner ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Jeffrey H Cooper director BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Frazier Healthcare V, Lp 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Christopher Peetz officer: Chief Financial Officer C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Regado Biosciences (Regado Biosciences) Headlines

No Headlines